Seung Hahm, Ph.D.

Seung Hahm, Ph.D. is an experienced professional with a diverse background in the field of pharmacology. Seung has held various roles in reputable companies and academic institutions.

Starting in 1993, Seung Hahm worked at the Icahn School of Medicine at Mount Sinai, initially as a Postdoctoral Fellow. In 1998, they transitioned to the role of Research Assistant Professor/Instructor.

In 2001, Seung Hahm joined Amgen as a Scientist and made significant contributions until 2005. Seung then moved to Pfizer, where they served as a Principal Scientist/Senior Scientist II in In Vivo Biology, specifically in the field of Metabolic Diseases. Seung'stenure at Pfizer lasted from 2005 to 2009.

Following their time at Pfizer, Seung Hahm joined Novartis as an Investigator III from 2009 to 2015, further expanding their expertise in the industry.

In 2015, Seung Hahm assumed the position of Sr. Director/Director, Head of In Vivo Pharmacology at Navitor Pharmaceuticals. Seung played a crucial role in advancing the company's pharmacology initiatives and held this position until the end of 2021. Subsequently, they continued to contribute to Navitor Pharmaceuticals as a Head of Pharmacology (Consultant) starting in January 2022.

Finally, Seung Hahm briefly worked as the Vice President of Biology at 1910 Genetics from January 2022 until August 2022 before transitioning to their current role as a Head of Pharmacology (Consultant) at Navitor Pharmaceuticals.

Throughout their career, Seung Hahm has demonstrated a strong aptitude for driving innovative solutions and has made significant contributions to the field of pharmacology.

Seung Hahm, Ph.D. completed a Bachelor of Science degree in Chemistry from Cameron University from 1984 to 1989. Following this, from 1989 to 1993, Dr. Hahm pursued a Doctor of Philosophy degree in Biochemistry from the University of Arkansas.